April Fools' Day pranks from around Colorado. Did you fall for any of these?
Day pranks come in all shapes and sizes, and on Tuesday Colorado businesses, county governments and even the governor himself ...
Naturepedic unveil new mattress toppers that promise to add organic, cloud-like comfort to your bed
Combining eco-conscience with sleep science, Naturepedic is known for producing some of the best organic mattresses of the ...
WWMT1d
Destructive storms, a Kalamazoo shootout, a fatal Amish buggy crash & more top stories
A Kalamazoo Township police officer and a suspect were hurt after shots were fired in Kalamazoo on Thursday, according to the ...
Lilly's Lepodisiran Achieves 94% Heart Disease Risk Reduction in Groundbreaking Phase 2 Trial
Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.
Millions Share a Deadly Genetic Heart Risk. This Experimental Drug Could Be a Game Changer
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
Mother's Day sessions at Albrighton alpaca farm deliver bales of fun to lucky mums
Wildwood Alpacas near Albrighton hosted extra-special, ticketed Mother's Day sessions from Friday (March 28) to Sunday. The ...
Precision Medicine Online1d
Eli Lilly Drug Cuts Lp(a) in Trial, Raising Its Prospects for Treating Cardiovascular Disease
Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...
Applied Clinical Trials Online1d
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...
BioSpace1d
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
pharmaphorum1d
ACC25: Positive results with Lilly's Lp(a)-lowering drug
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
PharmiWeb1d
Lilly's lepodisiran reduced levels of genetically…
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...